Shopping Cart
- Remove All
- Your shopping cart is currently empty
MYLS22 is a first-in-class and selective inhibitor of optic atrophy 1 (OPA1) . MYLS22 can target endothelial OPA1 to curtail tumor growth and inhibits angiogenesis by impinging on NFkB activity and on angiogenic gene expression. It with anti-angiogenesis and anti-cancer activity.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
2 mg | $35 | In Stock | |
5 mg | $57 | In Stock | |
10 mg | $97 | In Stock | |
25 mg | $166 | In Stock | |
50 mg | $253 | In Stock | |
100 mg | $391 | In Stock | |
200 mg | $587 | In Stock | |
500 mg | $929 | In Stock | |
1 mL x 10 mM (in DMSO) | $63 | In Stock |
Description | MYLS22 is a first-in-class and selective inhibitor of optic atrophy 1 (OPA1) . MYLS22 can target endothelial OPA1 to curtail tumor growth and inhibits angiogenesis by impinging on NFkB activity and on angiogenic gene expression. It with anti-angiogenesis and anti-cancer activity. |
In vivo | MYLS22 (10 mg/kg/die;?peritumoral injection;?every 2 days for 14 days) causes the tumor growth curtailed mice |
Molecular Weight | 443.52 |
Formula | C24H21N5O2S |
Cas No. | 306959-01-3 |
Smiles | Cc1nn(-c2ccccc2)c2sc(cc12)C(=O)Nc1c(C)n(C)n(-c2ccccc2)c1=O |
Relative Density. | no data available |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 45 mg/mL (101.46 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.